Commentary & Perspectives

The New Blueprint for Vaccine Development

ReiThera’s leaders discuss platform technologies, scalable manufacturing, and the trust needed to strengthen global vaccine preparedness

  • March 12, 2026

  • 6 min

Share

Vaccine development is evolving through platform-based technologies, rapid-response manufacturing, and global collaboration, as highlighted by Claudio Panzarella and Francesca Vidali. Key trends include the adoption of adaptable viral vectors and mRNA technologies, which enable faster responses to emerging pathogens without compromising quality. The COVID-19 pandemic has stressed the importance of supply chain resilience and strategic partnerships among CDMOs. Moreover, public trust and transparent communication are essential for countering anti-vaccine sentiments and fostering international cooperation in vaccine R&D.

Original Source(s)

The New Blueprint for Vaccine Development

  • March 12, 2026

Related Content

RSV Vaccine Eligibility Expands

Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.

Clinicians Warn of Fatal Measles Brain Disease

Doctors caution that measles infection can lead to SSPE, a rare fatal neurologic disease that may appear years later.

The 60 Percent Diagnostic Gap in M/E

What earlier mNGS testing could mean for labs and clinicians